Clinical use of whole genome sequencing for Mycobacterium tuberculosis

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Witney, Adam A ^a   Cosgrove, Catherine A ^a,b   Arnold, Amber ^b   Hinds, Jason ^a   Stoker, Neil G ^a   Butcher, Philip D ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Multidrug resistance; Tuberculosis; Whole genome sequencing

Indexed keywords

ANTIBIOTIC AGENT; MOXIFLOXACIN; PROTIONAMIDE; TUBERCULOSTATIC AGENT;

BACTERIUM IDENTIFICATION; DIAGNOSTIC KIT; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE TRANSMISSION; DRUG SENSITIVITY; GENE SEQUENCE; GENOTYPING TECHNIQUE; HEALTH CARE COST; HEPATITIS; HEREDITY; HUMAN; IMMUNOASSAY; MENTAL DISEASE; MOLECULAR GENETICS; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PHENOTYPE; REVIEW; SEQUENCE ANALYSIS; SPUTUM ANALYSIS; TUBERCULOSIS; VOMITING; WHOLE GENOME SEQUENCING; BACTERIAL GENOME; DNA SEQUENCE; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETIC POLYMORPHISM; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; PROCEDURES; UNITED KINGDOM;

ANTITUBERCULAR AGENTS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOME, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT; UNITED KINGDOM;

EID: 84963983883     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0598-2     Document Type: Review

References (45)

1. Loman NJ, Pallen MJ. XDR-TB genome sequencing: a glimpse of the microbiology of the future. Future Microbiol. 2008;3(2):111-3.
2. Public Health England. Tuberculosis in the UK: 2015 report (presenting data to end of 2014). London: Public Health England 2015. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/464914/TB_Annual_Report_2015.pdf.
3. Thorpe TC, Wilson ML, Turner JE, DiGuiseppi JL, Willert M, Mirrett S, et al. BacT/Alert: an automated colorimetric microbial detection system. J Clin Microbiol. 1990;28(7):1608-12.
4. World Health Organization (WHO). Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Geneva: WHO; 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK148644.
5. Lange C, Abubakar I, Alffenaar JW, Bothamley G, Caminero JA, Carvalho ACC, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23-63.
6. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol. 2010;48(1):229-37.
7. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol. 2005;43(8):3699-703.
8. Hillemann D, Rüsch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol. 2009;47(6):1767-72.
9. Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, et al. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Med. 2015;7(1):51.
10. Zhang H, Li D, Zhao L, Fleming J, Lin N, Wang T, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nat Genet. 2013;45(10):1255-60.
11. Walker TM, Kohl TA, Omar SV, Hedge J, Elias CDO, Bradley P, et al. Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis. 2015;15(10):1193-202.
12. Hillemann D, Hoffner S, Cirillo D, Drobniewski F, Richter E, Rüsch-Gerdes S, et al. First evaluation after implementation of a quality control system for the second line drug susceptibility testing of Mycobacterium tuberculosis joint efforts in low and high incidence countries. PLoS One. 2013;8(10):e76765.
13. Sanchez-Padilla E, Merker M, Beckert P, Jochims F, Dlamini T, Kahn P, et al. Detection of drug-resistant tuberculosis by Xpert MTB/RIF in Swaziland. N Engl J Med. 2015;372(12):1181-2.
14. Siu GKH, Zhang Y, Lau TCK, Lau RWT, Ho PL, Yew WW, et al. Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2011;66(4):730-3.
15. Jacobson KR, Theron D, Victor TC, Streicher EM, Warren RM, Murray MB. Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis. 2011;53(4):369-72.
16. Malik S, Willby M, Sikes D, Tsodikov OV, Posey JE. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One. 2012;7(6):e39754.
17. Feasey NA, Pond M, Coleman D, Solomon AW, Cosgrove CA, Delgado R, et al. Moxifloxacin and pyrazinamide susceptibility testing in a complex case of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2011;15(3):417-20.
18. Pang Y, Lu J, Wang Y, Song Y, Wang S, Zhao Y. Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(2):893-900.
19. Jamieson FB, Guthrie JL, Neemuchwala A, Lastovetska O, Melano RG, Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J Clin Microbiol. 2014;52(6):2157-62.
20. Sirgel FA, Warren RM, Böttger EC, Klopper M, Victor TC, van Helden PD. The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks. PLoS One. 2013;8(3):e59414.
21. Domínguez J, Boettger EC, Cirillo D, Cobelens F, Eisenach KD, Gagneux S, et al. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. Int J Tuberc Lung Dis. 2016;20(1):24-42.
22. Supply P, Allix C, Lesjean S, Cardoso-Oelemann M, Rüsch-Gerdes S, Willery E, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44(12):4498-510.
23. Gardy JL, Johnston JC, Sui SJH, Cook VJ, Shah L, Brodkin E, et al. Whole-genome sequencing and social-network analysis of a tuberculosis outbreak. N Engl J Med. 2011;364(8):730-9.
24. Török ME, Reuter S, Bryant J, Köser CU, Stinchcombe SV, Nazareth B, et al. Rapid whole-genome sequencing for investigation of a suspected tuberculosis outbreak. J Clin Microbiol. 2013;51(2):611-4.
25. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ, et al. Whole-genome sequencing to delineate Mycobacterium tuberculosis outbreaks: a retrospective observational study. Lancet Infect Dis. 2013;13(2):137-46.
26. Pankhurst LJ, del Ojo EC, Votintseva AA, Walker TM, Cole K, Davies J, et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med. 2016;4(1):49-58.
27. Sturdy A, Goodman A, José RJ, Loyse A, O'Donoghue M, Kon OM, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66(8):1815-20.
28. National Institute for Health and Care Excellence (NICE). Tuberculosis. NICE guidelines NG33. London: NICE; 2016. Available from: http://www.nice.org.uk/guidance/ng33/.
29. Witney AA, Gould KA, Arnold A, Coleman D, Delgado R, Dhillon J, et al. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol. 2015;53(5):1473-83.
30. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford ABH, Marais BJ, et al. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother. 2015;70(4):1198-202.
31. Koser C, Bryant JM, Becq J, Torok ME, Ellington MJ, Marti-Renom MA, et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med. 2013;369(3):290-2.
32. Brown AC, Bryant JM, Einer-Jensen K, Holdstock J, Houniet DT, Chan JZM, et al. Rapid Whole-genome sequencing of Mycobacterium tuberculosis isolates directly from clinical samples. J Clin Microbiol. 2015;53(7):2230-7.
33. Bryant JM, Lipman M, Breuer J. Personalizing therapy for multidrug resistant TB: the potential of Rapid Whole Genome Sequencing. Expert Rev Anti Infect Ther. 2016;14(1):1-3.
34. McPherson JD. A defining decade in DNA sequencing. Nat Methods. 2014;11(10):1003-5.
35. Judge K, Harris SR, Reuter S, Parkhill J, Peacock SJ. Early insights into the potential of the Oxford Nanopore MinION for the detection of antimicrobial resistance genes. J Antimicrob Chemother. 2015;70(10):2775-8.
36. Hatem A, Bozdağ D, Toland AE, Çatalyürek ÜV. Benchmarking short sequence mapping tools. BMC Bioinformatics. 2013;14:184.
37. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16):2078-9.
38. Garrison E, Marth G. Haplotype-based variant detection from short-read sequencing. ArXiv12073907 Q-Bio; 2012. Available from: http://arxiv.org/abs/1207.3907.
39. Feuerriegel S, Schleusener V, Beckert P, Kohl TA, Miotto P, Cirillo DM, et al. PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol. 2015;53(6):1908-14.
40. Bradley P, Gordon NC, Walker TM, Dunn L, Heys S, Huang B, et al. Rapid antibiotic-resistance predictions from genome sequence data for Staphylococcus aureus and Mycobacterium tuberculosis. Nat Commun. 2015;6:10063.
41. Global Microbial Identifier (GMI). Available from: http://www.globalmicrobialidentifier.org/.
42. Stucki D, Gagneux S. Single nucleotide polymorphisms in Mycobacterium tuberculosis and the need for a curated database. Tuberculosis (Edinb). 2013;93(1):30-9.
43. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med. 2009;6(2):e2.
44. Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194 Suppl 1:S51-8.
45. Relational Sequencing TB Data Platform (ReSeqTB). Available from: https://platform.reseqtb.org/.